Anetakis Constantine, Mitka Stella, Hadjidimitriou Maria, Anagnostopoulos Konstantinos, Lialiaris Theodoros
Laboratory of Clinical Chemistry, Faculty of Biomedical Sciences, School of Health Sciences, Alexandrian Campus of International Hellenic University, 57400 Sindos, Thessaloniki, Greece.
Bioanalysis diagnostic laboratory, D. Gounari 33, 54622 Thessaloniki, Greece.
Rep Biochem Mol Biol. 2024 Jan;12(4):652-663. doi: 10.61186/rbmb.12.4.652.
An ongoing debate has been raised on whether is better to use total or free calcidiol as a screening test in the population.
In winter and summer, free calcidiol, total calcitriol, and vitamin D binding protein (DBP) concentrations were determined by immunoenzymatic assays in 326 adults (161 males, 165 females). These included 99 osteoporotic patients, 53 type 1 and 51 type 2 diabetics, and 123 athletic healthy persons, all from northern Greece.
In the whole sample, free calcidiol mean concentrations differed significantly (p < 0.001) between males (5.53 pg/ml) and females (4.68 pg/ml). Free calcidiol was significantly greater in the athletic healthy group (6.02 pg/ml) than in the three patient groups, and lowest in the osteoporosis group (3.69 pg/ml). Total calcitriol mean concentration did not differ significantly between genders in the whole sample (p = 0.896) or in the study groups, except for type 2 diabetics (males 38.33 pg/ml, females 54.52 pg/ml, p = 0.001). It was significantly less in the osteoporotics (34.61 pg/ml) than in the athletic healthy group (41.65 pg/ml, p = 0.037) and type 1 diabetics (43.73 pg/ml, p = 0.030), whereas it did not differ significantly between the other study groups. The DBP mean concentrations were not significantly different between genders in the whole sample and the study groups nor among the study groups (p = 0.467).
Comparisons with our previously reported results of total calcidiol suggest the measurement of free calcidiol offers nothing more than that, and total calcitriol is not a sensitive measure for assessing vitamin D status.
关于在人群中使用总骨化二醇还是游离骨化二醇作为筛查指标更好,一直存在争论。
在冬季和夏季,采用免疫酶法对326名成年人(161名男性,165名女性)测定游离骨化二醇、总骨化三醇和维生素D结合蛋白(DBP)浓度。这些人包括99名骨质疏松患者、53名1型糖尿病患者、51名2型糖尿病患者以及123名来自希腊北部的健康运动员,
在整个样本中,男性(5.53 pg/ml)和女性(4.68 pg/ml)的游离骨化二醇平均浓度差异显著(p < 0.001)。健康运动员组的游离骨化二醇(6.02 pg/ml)显著高于三个患者组,在骨质疏松组中最低(3.69 pg/ml)。在整个样本中,总骨化三醇平均浓度在性别之间没有显著差异(p = 0.896),在各研究组中也是如此,但2型糖尿病患者除外(男性38.33 pg/ml,女性54.52 pg/ml,p = 0.001)。骨质疏松患者的总骨化三醇(34.61 pg/ml)显著低于健康运动员组(41.65 pg/ml,p = 0.037)和1型糖尿病患者(43.73 pg/ml,p = 0.030),而在其他研究组之间没有显著差异。整个样本、各研究组以及各研究组之间的DBP平均浓度没有显著差异(p = 0.467)。
与我们之前报道的总骨化二醇结果相比,游离骨化二醇的测量并无更多优势,且总骨化三醇并非评估维生素D状态的敏感指标。